Berberine: Difference between revisions

From Glioblastoma Treatments
Jump to navigationJump to search
(Created page with "{{TreatmentInfo |drug_name=Berberine |FDA_approval=No |used_for=Glioblastoma Multiforme (GBM) |OS_without=Not explicitly mentioned; refer to specific studies for detailed metrics. |OS_with=Studies suggest enhancement of temozolomide efficacy in resistant GBM cases, potentially improving overall survival rates. |clinical_trial_phase=Pre-clinical (in vitro and in vivo studies) |common_side_effects=Not specifically listed for GBM treatment; generally well-tolerated but can...")
 
(Blanked the page)
Tag: Blanking
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{TreatmentInfo
 
|drug_name=Berberine
|FDA_approval=No
|used_for=Glioblastoma Multiforme (GBM)
|OS_without=Not explicitly mentioned; refer to specific studies for detailed metrics.
|OS_with=Studies suggest enhancement of temozolomide efficacy in resistant GBM cases, potentially improving overall survival rates.
|clinical_trial_phase=Pre-clinical (in vitro and in vivo studies)
|common_side_effects=Not specifically listed for GBM treatment; generally well-tolerated but can include gastrointestinal discomfort at high doses.
|mechanism_of_action=Berberine exhibits anticancer activity by inhibiting cell proliferation and invasion, suppressing tumor angiogenesis, and inducing cell apoptosis. It has shown potential to sensitize temozolomide-resistant GBM cells, suggesting its utility in overcoming treatment resistance.
|notes=Recent studies underscore Berberine's promising role against GBM, especially in temozolomide-resistant cases. Its broad pharmacological actions against cancer, including GBM, spotlight its potential as a multi-targeted therapeutic agent. Despite the promising laboratory and animal model results, further research is needed to fully understand its clinical implications and optimal usage in GBM treatment.
|category=Nutraceuticals
}}

Latest revision as of 09:29, 27 March 2024